Seasonal influenza is caused by two subtypes of influenza A and two lineages of influenza B. Although trivalent influenza vaccines (TIVs) contain both circulating A strains, they contain only a single B-lineage strain. This can lead to mismatches between the vaccine and predominant circulating B lineages, a concern especially for at-risk populations. Quadrivalent influenza vaccines (QIVs) containing a strain from both B lineages have been developed to improve protection against influenza. Here, we used a cost-utility model to examine whether switching from TIV to QIV would be cost-effective for the at-risk population in Italy. Costs were estimated from the payer and societal perspectives. The discount rate for outcomes was 3.0%. Univariate and probabilistic sensitivity analyses were performed to examine the effects of variations in parameters. Switching from TIV to QIV in Italy was estimated to increase quality-adjusted life-years (QALYs) and produce cost savings, including (sic)1.6 million for hospitalization and approximately (sic)2 million in productivity. The incremental cost-effectiveness ratio was (sic)23,426 per QALY from a payer perspective and (sic)21,096 per QALY from a societal perspective. Switching to QIV was most cost-effective for individuals >= 65 years of age ((sic)19,170 per QALY). Probabilistic sensitivity analysis showed that the switching from TIV to QIV would be cost-effective for > 91% of simulation at a maximum willingness-to-pay threshold of (sic)40,000 per QALY gained. Although the model did not take herd protection into account, it predicted that the switch from TIV to QIV would be cost-effective for the at-risk population in Italy.
Mennini, F.s., Bini, C., Marcellusi, A., Rinaldi, A., Franco, E. (2018). Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 14(8), 1867-1873 [10.1080/21645515.2018.1469368].
Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
Mennini F. S.Methodology
;Franco E.
2018-01-01
Abstract
Seasonal influenza is caused by two subtypes of influenza A and two lineages of influenza B. Although trivalent influenza vaccines (TIVs) contain both circulating A strains, they contain only a single B-lineage strain. This can lead to mismatches between the vaccine and predominant circulating B lineages, a concern especially for at-risk populations. Quadrivalent influenza vaccines (QIVs) containing a strain from both B lineages have been developed to improve protection against influenza. Here, we used a cost-utility model to examine whether switching from TIV to QIV would be cost-effective for the at-risk population in Italy. Costs were estimated from the payer and societal perspectives. The discount rate for outcomes was 3.0%. Univariate and probabilistic sensitivity analyses were performed to examine the effects of variations in parameters. Switching from TIV to QIV in Italy was estimated to increase quality-adjusted life-years (QALYs) and produce cost savings, including (sic)1.6 million for hospitalization and approximately (sic)2 million in productivity. The incremental cost-effectiveness ratio was (sic)23,426 per QALY from a payer perspective and (sic)21,096 per QALY from a societal perspective. Switching to QIV was most cost-effective for individuals >= 65 years of age ((sic)19,170 per QALY). Probabilistic sensitivity analysis showed that the switching from TIV to QIV would be cost-effective for > 91% of simulation at a maximum willingness-to-pay threshold of (sic)40,000 per QALY gained. Although the model did not take herd protection into account, it predicted that the switch from TIV to QIV would be cost-effective for the at-risk population in Italy.File | Dimensione | Formato | |
---|---|---|---|
2018_Cost-effectiveness_of_switching_from_trivalent_to_.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
875.94 kB
Formato
Adobe PDF
|
875.94 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.